Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib plus TACE versus placebo plus TACE in unresectable hepatocellular carcinoma
ISRCTN93375053Phase 3Completed
- Sponsor
- University College London
- Start
- Nov 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of sorafenib and doxorubicin in hepatocellular carcinoma (HCC) (2 arms), sponsored by University College London. Primary endpoint: Progression-free survival. Started Nov 2010; status: completed.
02
Drugs
sorafenibdoxorubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ISRCTN93375053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN93375053.